Secondary haemophagocytic lymphohistiocytosis (SHFLH) is a rare, potentially fatal disorder, most commonly caused by the Epstein–Barr virus. It is characterized by neoplastic proliferation of cells that belong to the monocyte–macrophage system and by varied clinical expression.
A girl aged 3 years and 7 months was hospitalized due to continuing high febricity, yellow skin colouring, hepatosplenomegaly and cytopenia in a complete blood count (CBC). Four weeks before hospitalization, she had a lacunar angina and lymphadenopathy.
A low number of erythrocytes, leukocytes and thrombocytes were noted in CBC, with anaemia and the presence of virocytes in a peripheral blood smear. Biochemical blood analyses indicated hyperbilirubinaemia, increased values of transaminases, lactic dehydrogenase, ferritin, triglycerides, D-dimer, acceleration of the activated partial thromboplastin time and decreased values of fibrinogen, with increased values of C-reactive protein and procalcitonin. Using an ultrasound examination of the abdomen, hepatosplenomegaly was perceived; using echocardiographic examination, pericardium layering was noticed; and using a roentgen graphic picture of the lungs, the presence of pleural effusion was detected. In a bone marrow biopsy, the percentage of blasts did not exceed 25%, and rare chemophagocytes were noticed. Using serologic tests, positivity to Epstein-Barr virus in IgM class was demonstrated.
According to the criteria by Histiocyte Society, there were sufficient criteria to establish a diagnosis of SHFLH. With the exception of symptomatic therapies, according to the protocol for SHFLH treatment, a double antibiotic therapy and IV immunoglobulins were given, to which the patient responded with a clinical and laboratory recovery. Therefore, there was no demand for a treatment protocol with cytostatics or bone marrow transplantation.
To resolve a differential diagnosis dilemma in solving cases of uncertain febrile neutropenia.
1. Lipton JM, Arceci RJ. Histiocytic disorders. In: Hoffman R, Edward B, eds. Hematology: basic principles and practice. 4th ed. Philadelphia: Churchill Livingstone. 2005; 857–67.
2. Ladisch S. Histiocytosis syndrome in childhood. In: Behrman ER, Kliegman MR, Jenson BH. NELSON Textbook of pediatrics, vol 2, 17th ed. Belgrade: Saunders, Bard 2009; 1727–30. (translated)
3. Favara BE, Feller AC, Pauli M et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol. 1997; 29(3): 157–66.
4. Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann Med. 2006; 38(1): 20–31.
5. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012; (63): 233–46.
6. Feldmann J, Le Deist F, Ouachée–Chardin M et al. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2002; 117(4): 965–72.
7. Feldmann J, Callebaut I, Raposo G et al. Munc 13–4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003; 115(4): 461–73.
8. Ohadi M, Lalloz MR, Sham P et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3–22 by homozygosity mapping. Am J Hum Genet. 1999; 64(1): 165–71.
9. Dufourcq–Lagelouse R, Jabado N, Le Deist F et al. Linkage of familial hemophagocytic lymphohistiocytosis to 10q21–22 and evidence for heterogeneity. Am J Hum Genet. 1999 Jan; 64(1): 172–9.
10. Stepp SE, Dufourcq–Lagelouse R, Le Deist F et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999; 286(5446): 1957–9.
11. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002; 99(1): 61–6
12. Ansuini V, Rigante D, Esposito S. Debate around infection–dependent hemophagocytic syndrome in pediatrics. BMC Infect Dis. 2013; (13): 13–15.
13. Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis. 2000; 6(6): 601–8.
14. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection– and malignancy–associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998; 12(2): 435–44.
15. Danish EH, Dahms BB, Kumar ML. Cytomegalovirus– associated hemophagocytic syndrome. Pediatrics. 1985; 75(2): 280-3.
16. Bhatia S, Bauer F, Bilgrami SA. Candidiasis–associated hemophagocytic lymphohistiocytosis in a patient infected with human immunodeficiency virus. Clin Infect Dis. 2003; 37(11): 161–6.
17. Watanabe T, Okazaki E, Shibuya H. Influenza A virus– associated encephalopathy with haemophagocytic syndrome. Eur J Pediatr. 2003; 162(11): 799–800.
18. Kaya Z, Oztürk G, Gürsel T, Bozdayi G. Spontaneous resolution of hemophagocytic syndrome and disseminated intravascular coagulation associated with Parvovirus B19 infection in a previously healthy child. Jpn J Infect Dis. 2005; 58(3): 149–51.
19. Tuon FF, Gomes VS et al. Hemophagocytic syndrome associated with hepatitis A: case report and literature review. Rev Inst Med Trop Sao Paulo. 2008; 50(2): 123–7.
20. Brastianos PK, Swanson JW, Torbenson M, Sperati J, Karakousis PC. Tuberculosis–associated haemophagocytic syndrome. Lancet Infect Dis. 2006; 6(7): 447–54.
21. Cascio A, Giordano S, Dones P, Venezia S, Iaria C, Ziino O. Haemophagocytic syndrome and rickettsial diseases. J Med Microbiol. 2011; 60(Pt 4): 537–42.
22. Gosh JB, Roy M, Bala A. Infection associated with Hemophagocytic Lymphohistiocytosis triggered by nosocomial infection. Oman Med J. 2009; 24(3): 223–5.
23. Cascio A, Pernice LM et al. Secondary hemophagocytic lymphohistiocytosis in zoonoses. A systematic review. Eur Rev Med Pharmacol Sci. 2012; 16(10): 1324–37.
24. Gagnaire MH, Galambrun C, Stéphan JL. Hemophagocytic syndrome: a misleading complication of visceral leishmaniasis in children – a series of 12 cases. Pediatrics. 2000; 106(4): E58.
25. Onishi R, Namiuchi S. Hemophagocytic syndrome in a patient with rheumatoid arthritis. Intern Med. 1994; 33(10): 607–11.
26. Wong KF, Hui PK, Chan JK, Chan YW, Ha SY. The acute lupus hemophagocytic syndrome. Ann Intern Med. 1991; 114(5): 387–90.
27. Henter JI, Horhe A, Arico M et al. HLH–2004: Diagnostic an therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Pediatr Blood Cancer. 2007; 48(2): 124–31.
28. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol. 1991; 18(1): 29–33.
29. Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013; 139(6):713–27.
30. Tang YM, Xu XJ. Advances in hemophagocytic lymphohistiocytosis: pathogenesis, early diagnosis/differential diagnosis, and treatment. Scientific World Journal. 2011; 11: 697–708.
31. Konuş OL, Ozdemir A, Akkaya A, Erbaş G, Celik H, Işik S. Normal liver, spleen and kidney dimensions in neonates, infants, and children: evaluation with sonography. AJR Am J Roentgenol. 1998; 171(6): 1693–8.
32. Rademacher C, Hartmann D, Spiethoff A, Jakobs R. Ferritin and soluble interleukin–2–receptor in the diagnosis of fever of unknown origin. Dtsch Med Wochenschr. 2014; 139(1-2): 23–7.
33. Lehmberg K, McClain KL, Janka GE, Allen CE. Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2014 Apr 21. [Epub ahead of print] PubMed PMID: 24753034.
34. Imashuku S, Hibi S et al. Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood. 1995; 86(12): 4706–7.
35. Wang LL, Hu YX, Chen WF et al. Significance of soluble interleukin-2 receptor and NK cell activity in patients with hemophagocytic lymphohistiocytosis. Zhongguo Shi Yan Xue Ye XueZaZhi. 2012; 20(2): 401–4.
36. Sloma I, Vincent H, Addebbous A, Rivoisy C, Turhan GA, Michot JM. Haemophagocytic histiocyte in a peripheral blood film. Br J Haematol. 2014; 165(2): 163.
37. Jabado N, McCusker C, BasileGde S. Pediatric hemophagocytic syndromes: a diagnostic and therapeutic challenge. Allergy Asthma Clin Immunol. 2005; 1(4): 142–60.
38. Kobayashi S, Ito M, Sano H et al. Clinical analysis of combination therapy for febrile neutropenic patients in childhood cancer. Pediatr Int. 2013; 55(1): 65–71.
39. Raghavendra M, Hoeg RT, Bottner WA, Agger WA. Management of neutropenic fever during a transition from traditional hematology/oncology service to hospitalist care. WMJ. 2014; 113(2): 53–8.
40. Hung KC, Chiu HH, Tseng YC et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. J Microbiol Immunol Infect. 2003; 36(4): 254–9.
41. Biondi E, McCulloh R, Alverson B, Klein A, Dixon A, Ralston S. Treatment of Mycoplasma Pneumonia: A Systematic Review. Pediatrics. 2014; 133(6):1081–90.
42. Aytaç S, Yildirim I, Ceyhan M et al. Risks and outcome of fungal infection in neutropenic children with hematologic diseases. Turk J Pediatr. 2010; 52(2): 121–5.
43. Rajajee S, Ashok I, Manwani N, Rajkumar J, Gowrishankar K, Subbiah E. Profile of Hemophagocytic Lymphohistiocytosis; Efficacy of Intravenous Immunoglobulin Therapy. Indian J Pediatr. 2014 May 9. [Epub ahead of print] PubMed PMID: 24806152.
44. Scott R, Robb-Smith A. Histiocytic medullary reticulosis. Lancet. 1939; (2): 194–8.
45. Farquhar J, Claireaux A. Familial haemophagocytic reticulosis. Arch Dis Child. 1952; 27(136): 519–525.
46. Boake WC; Card WH, Kimmey JF. Histiocytic Medullary Reticulosis, Concurrence in Father and Son. Arch Intern Med. 1965; 116(2): 245–52.
47. Henter JI, Ehrnst A, Andersson J, Elinder G. Familial hemophagocytic lymphohistiocytosis and viral infections. Acta Paediatr. 1993; 82(4): 369–372.
48. Vaiselbuh SR, Bryceson YT, Allen CE, Whitlock JA, Abla O. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014; 61(7): 1329–35.
49. Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2013; 2013: 605–11.
50. Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis and treatment. J Pediatr. 2013; 163(5): 1253–9.
51. Balwierz W, Czogała M, Pawińska–Wasikowska K, Cwiklińska M, Walicka–Soja K. Hemophagocytic lymphohistiocytosis: diagnostic problems in pediatrics. Przegl Lek. 2010; 67(6): 417–24.
52. Real E, Gomez A, Alcaraz MJ, Saez AI, Pastor E, Grau E. Fulminant hemophagocytic syndrome as presenting feature of T–cell lymphoma and Epstein–Barr virus infection. Haematologica. 2000; 85(4): 439–40.
53. Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol. 2013; 161(5): 609–22.
54. Guo X, Li Q, Zhou CY, Zhao YN. Clinical analysis of Epstein–Barr virus–associated hemophagocytic syndrome in children. Zhongguo Shi Yan Xue Ye XueZa-Zhi. 2013; 21(2): 460–4.
55. Liapis K, Apostolidis J, Delimpasis S. EBV–associated hemophagocytic syndrome. Am J Hematol. 2011; 86(5): 422.
56. Henter JI, Nennesmo I. Neuropathologic findings and neurologic symptoms in twenty–three children with hemophagocytic lymphohistiocytosis. J Pediatr. 1997; 130(3): 358–65.
57. Haddad E, Sulis ML, Jabado N, Blanche S, Fischer A, Tardieu M. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood. 1997; 89(3): 794–800.
58. Janković G. Aplastic anemia. In: D. Manojlovic. Internal Medicine, 5th ed. Belgrade: The Institute for Textbooks, 2009; 1019–21.
59. Čolović M. Leucemias. In: D. Manojlovic. Internal Medicine, 5th ed. Belgrade: The Institute for Textbooks, 2009; 1031–43.
60. Aulbert E, Fromm H, Hornemann H. Ferritin in acute leukemia. Serum ferritin concentration as a nonspecific tumor marker for M1 and M2 myeloid leukemia. Med Klin (Munich). 1991; 86(6): 297–304.
61. Huang SC, Chen JS, Cheng CN, Yang YJ. Hypoalbuminaemia is an independent predictor for hemophagocytic lymphohistiocytosis in childhood Epstein–Barr virus– associated infectious mononucleosis. Eur J Haematol. 2012; 89(5): 417–22.
62. Eid A, Keddissi JI, Kinasewitz GT. Hypoalbuminemia as a cause of pleural effusions. Chest 1999; 115(4): 1066-9.
63. Tutor JD. Chylothorax in infants and children. Pediatrics. 2014; 133(4):722–33.
64. Popović G. Pleural effusions: a special review of pleural effusions in extrapulmonary disease. Pneumon 2010; 47(1-2): 73–80.
65. Kogawa K, Sato H, Asano T et al. Prognostic factors of Epstein–Barr virus–associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group. Pediatr Blood Cancer. 2014; 61(7): 1257–62.
66. Ishii E, Ohga S et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007; 86(1): 58–65.
67. Chen CJ, Huang YC et al. Hemophagocytic syndrome: a review of 18 pediatric cases. J Microbiol Immunol Infect. 2004; 37(3): 157–63.
68. Bakhshi S, Pautu JL. EBV associated hemophagocytic lymphohistiocytosis with spontaneous regression. Indian Pediatr. 2005; 42(12): 1253–5.
69. Imashuku S. Treatment of Epstein–Barr virus–related hemophagocytic lymphohistiocytosis (EBV–HLH); update 2010. J Pediatr Hematol Oncol. 2011; 33(1): 35–9.
70. Marsh RA, Jordan MB, Filipovich AH. Reduced–intensity conditioning haematopoetic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward. Br J Haematol. 2011; 154(5): 556–63.
71. Shiraishi A, Ohga S, Doi T et al. Treatment choice of immunotherapy or further chemotherapy for Epstein–Barr virus–associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2012; 59(2): 265–70.
72. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus–associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2007; 29(8): 569–73.